Cohance Lifesciences Limited has informed the Exchange about Transcript
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences held an investor call following the resignation of Managing Director Dr. Prasada Raju, who is stepping down for personal reasons and will stay through the fiscal to aid transition. The company has restructured into three business verticals—Pharma CDMO (led by Yann D'Herve), API Plus (Gunjan Singh), and Specialty Chemicals (Amrit Singh)—now reporting directly to Executive Chairman Vivek Sharma, with a new platform COO joining shortly. Management reiterated its US$1 billion revenue target by 2030 and highlighted business momentum: four major CDMO customer orders completed, a large Japanese customer's Phase 3 order confirmed (triggering SuryaPet facility capitalization), and the oligonucleotide (Surya) unit in Nacharam on track for Q4 commissioning. The company has an in-house M&A team actively scouting niche tech acquisitions (ADC, oligonucleotide, differentiated capabilities) and plans to fund deals through internal cash while staying cash-positive. A Nacharam FTF unit OI classification issue is being addressed with U.S. FTA consultants, though it impacts less than 1% of EBITDA.
Investors should weigh the strategic clarity and strong commercial pipeline (Phase 3 orders, ADC contracts, Q4 oligo commissioning) against near-term execution risk from a second senior exit in quick succession and overlapping costs from the new leadership buildout. The $1B-by-2030 target and active inorganic strategy support the growth narrative, but management acknowledged minor short-term cost overlap, and the silent period meant no financial guidance was given.